Article
HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.
Antiviral research - 1 Oct 2018
Wei Lai, Omata Masao, Lim Young-Suk, Xie Qing, Hou Jin Lin, Jia Jidong, Hedskog Charlotte, Martin Ross, Doehle Brian, Yang Jenny, De-Oertel Shampa, Massetto Benedetta, Kersey Kathryn, Brainard Diana M, Svarovskaia Evguenia, Mo Hongmei, Han Kwang-Hyub, Mizokami Masashi, Duan Zhongping
Abstract excerpt
BACKGROUND & AIMS: Resistance associated substitutions (RAS) can reduce the efficacy of some direct-acting antiviral HCV regimens. Here, prevalence of RAS in genotype (GT) 1b, 2, 3, and 6 HCV-infected patients from Asian counties, North America and Europe are described and compared. METHODS: Pretreatment HCV RAS were assessed with 15% cutoff from patients enrolled in clinical trials of sofosbuvir-containing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.